Research programme: respiratory syncytial virus infection therapeutics - Enanta

Drug Profile

Research programme: respiratory syncytial virus infection therapeutics - Enanta

Alternative Names: EDP 938; EP 023938; Non-fusion inhibitors - Enanta; RSV therapeutics - Enanta

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 06 Jan 2017 Enanta plans a phase I trial for Respiratory syncytial virs infections
  • 08 Aug 2016 Preclinical trials in Respiratory syncytial virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top